Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease

Journal of Medicinal Chemistry

Volumn 55, Issue 22, 2012, Pages 9708-9721

  Simoni, Elena ^a,b   Daniele, Simona ^a,c   Bottegoni, Giovanni ^a   Pizzirani, Daniela ^a   Trincavelli, Maria L ^c   Goldoni, Luca ^a   Tarozzo, Glauco ^a   Reggiani, Angelo ^a   Martini, Claudia ^c   Piomelli, Daniele ^a,d   Melchiorre, Carlo ^b   Rosini, Michela ^b   Cavalli, Andrea ^a,b  

^a ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 (7 ((3,5 DIMETHYLADAMANTAN 1 YL) AMINO)HEPTYL) 3 METHOXY 5,6,9,10,11,12 HEXAHYDRO 4AH BENZO[2,3]BENZOFURO[4,3 CD]AZEPIN 6 OL; ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITOR; DIZOCILPINE; GALANTAMINE; IFENPRODIL; MEMAGAL; MEMANTINE; N (3,5 DIMETHYLADAMANTAN 1 YL) 6 (6 HYDROXY 3 METHOXY 5,6,9,10 TETRAHYDRO 4AH BENZO[2,3]BENZOFURO[4,3 CD]AZEPIN 11(12H) YL)HEXANAMIDE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CHEMICAL COMPOSITION; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; IC 50; MOLECULAR DOCKING; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; RAT; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; ANIMALS; CELL PROLIFERATION; CEREBRAL CORTEX; CHOLINESTERASE INHIBITORS; COMPUTER SIMULATION; DRUG COMBINATIONS; DRUG DESIGN; FEASIBILITY STUDIES; GALANTAMINE; HUMANS; MALE; MEMANTINE; NEUROBLASTOMA; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84869994179     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3009458     Document Type: Article

References (50)

1. Alzheimer's Disease International, World Alzheimer Report. http://www.alz.co.uk/research/files/WorldAlzheimerReport2010ExecutiveSummary.pdf
2. Citron, M. Alzheimer's disease: strategies for disease modification Nat. Rev. Drug Discovery 2010, 9, 387-398
3. Nordberg, A. Neuroreceptor changes in Alzheimer disease Cerebrovasc. Brain Metab. Rev. 1992, 4, 303-328
4. Palmer, A. M.; Gershon, S. Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic? FASEB J. 1990, 4, 2745-2752
5. Schmitt, B.; Bernhardt, T.; Moeller, H. J.; Heuser, I.; Frolich, L. Combination therapy in Alzheimer's disease: a review of current evidence CNS Drugs 2004, 18, 827-844
6. Patel, L.; Grossberg, G. T. Combination therapy for Alzheimer's disease Drugs Aging 2011, 28, 539-546
7. Hardingham, G. E.; Bading, H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders Nat. Rev. Neurosci. 2010, 11, 682-696
8. Xia, P.; Chen, H. S.; Zhang, D.; Lipton, S. A. Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses J. Neurosci. 2010, 30, 11246-11250
9. Samochocki, M.; Hoffle, A.; Fehrenbacher, A.; Jostock, R.; Ludwig, J.; Christner, C.; Radina, M.; Zerlin, M.; Ullmer, C.; Pereira, E. F.; Lubbert, H.; Albuquerque, E. X.; Maelicke, A. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors J. Pharmacol. Exp. Ther. 2003, 305, 1024-1036
10. Santos, M. D.; Alkondon, M.; Pereira, E. F.; Aracava, Y.; Eisenberg, H. M.; Maelicke, A.; Albuquerque, E. X. The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system Mol. Pharmacol. 2002, 61, 1222-1234
11. Moriguchi, S.; Marszalec, W.; Zhao, X.; Yeh, J. Z.; Narahashi, T. Mechanism of action of galantamine on N-methyl-D-aspartate receptors in rat cortical neurons J. Pharmacol. Exp. Ther. 2004, 310, 933-942
12. McGehee, D. S.; Heath, M. J.; Gelber, S.; Devay, P.; Role, L. W. Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors Science 1995, 269, 1692-1696
13. Geerts, H.; Grossberg, G. T. Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease J. Clin. Pharmacol. 2006, 46, 8S-16S
14. Grossberg, G. T.; Edwards, K. R.; Zhao, Q. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease J. Clin. Pharmacol. 2006, 46, 17S-26S
15. Cavalli, A.; Bolognesi, M. L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to combat neurodegenerative diseases J. Med. Chem. 2008, 51, 347-372
16. Zimmermann, G. R.; Lehar, J.; Keith, C. T. Multi-target therapeutics: when the whole is greater than the sum of the parts Drug Discovery Today 2007, 12, 34-42
17. Morphy, R.; Rankovic, Z. Fragments, network biology and designing multiple ligands Drug Discovery Today 2007, 12, 156-160
18. Hopkins, A. L. Network pharmacology: the next paradigm in drug discovery Nat. Chem. Biol. 2008, 4, 682-690
19. Small, G.; Dubois, B. A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch Curr. Med. Res. Opin. 2007, 23, 2705-2713
20. Bottegoni, G.; Favia, A. D.; Recanatini, M.; Cavalli, A. The role of fragment-based and computational methods in polypharmacology Drug Discovery Today 2012, 17, 23-34
21. Greenblatt, H. M.; Guillou, C.; Guenard, D.; Argaman, A.; Botti, S.; Badet, B.; Thal, C.; Silman, I.; Sussman, J. L. The complex of a bivalent derivative of galanthamine with torpedo acetylcholinesterase displays drastic deformation of the active-site gorge: implications for structure-based drug design J. Am. Chem. Soc. 2004, 126, 15405-15411
22. Rosini, M.; Simoni, E.; Bartolini, M.; Cavalli, A.; Ceccarini, L.; Pascu, N.; McClymont, D. W.; Tarozzi, A.; Bolognesi, M. L.; Minarini, A.; Tumiatti, V.; Andrisano, V.; Mellor, I. R.; Melchiorre, C. Inhibition of acetylcholinesterase, β-amyloid aggregation, and NMDA receptors in Alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush J. Med. Chem. 2008, 51, 4381-4384
23. Rook, Y.; Schmidtke, K. U.; Gaube, F.; Schepmann, D.; Wunsch, B.; Heilmann, J.; Lehmann, J.; Winckler, T. Bivalent β-carbolines as potential multitarget anti-Alzheimer agents J. Med. Chem. 2010, 53, 3611-3617
24. da Silva, R. A.; Estevam, I. H. S.; Bieber, L. W. Reductive methylation of primary and secondary amines and amino acids by aqueous formaldehyde and zinc Tetrahedron Lett. 2007, 48, 7680-7682
25. Ellman, G. L.; Courtney, K. D.; Andres, V., jr.; Featherstone, R. M. A new and rapid colorimetric determination of acetylcholinesterase activity Biochem. Pharmacol. 1961, 7, 88-90
26. Pang, Y. P.; Quiram, P.; Jelacic, T.; Hong, F.; Brimijoin, S. Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. Steps toward novel drugs for treating Alzheimer's disease J. Biol. Chem. 1996, 271, 23646-23649
27. Carlier, P. R.; Chow, E. S.; Han, Y.; Liu, J.; El Yazal, J.; Pang, Y. P. Heterodimeric tacrine-based acetylcholinesterase inhibitors: investigating ligand-peripheral site interactions J. Med. Chem. 1999, 42, 4225-4231
28. Piazzi, L.; Rampa, A.; Bisi, A.; Gobbi, S.; Belluti, F.; Cavalli, A.; Bartolini, M.; Andrisano, V.; Valenti, P.; Recanatini, M. 3-(4-[[Benzyl(methyl) amino]methyl]phenyl)-6,7-dimethoxy-2 H -2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation: a dual function lead for Alzheimer's disease therapy J. Med. Chem. 2003, 46, 2279-2282
29. Belluti, F.; Rampa, A.; Piazzi, L.; Bisi, A.; Gobbi, S.; Bartolini, M.; Andrisano, V.; Cavalli, A.; Recanatini, M.; Valenti, P. Cholinesterase inhibitors: xanthostigmine derivatives blocking the acetylcholinesterase-induced β-amyloid aggregation J. Med. Chem. 2005, 48, 4444-4456
30. Bolognesi, M. L.; Cavalli, A.; Valgimigli, L.; Bartolini, M.; Rosini, M.; Andrisano, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease J. Med. Chem. 2007, 50, 6446-6449
31. Cavalli, A.; Bolognesi, M. L.; Capsoni, S.; Andrisano, V.; Bartolini, M.; Margotti, E.; Cattaneo, A.; Recanatini, M.; Melchiorre, C. A small molecule targeting the multifactorial nature of Alzheimer's disease Angew. Chem., Int. Ed. Engl. 2007, 46, 3689-3692
32. Piazzi, L.; Cavalli, A.; Colizzi, F.; Belluti, F.; Bartolini, M.; Mancini, F.; Recanatini, M.; Andrisano, V.; Rampa, A. Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds Bioorg. Med. Chem. Lett. 2008, 18, 423-426
33. Lipton, S. A. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond Nat. Rev. Drug Discovery 2006, 5, 160-170
34. Bolognesi, M. L.; Cavalli, A.; Melchiorre, C. Memoquin: a multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer's disease Neurotherapeutics 2009, 6, 152-162
35. Mony, L.; Kew, J. N.; Gunthorpe, M. J.; Paoletti, P. Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential Br. J. Pharmacol. 2009, 157, 1301-1317
36. Chazot, P. L. The NMDA receptor NR2B subunit: a valid therapeutic target for multiple CNS pathologies Curr. Med. Chem. 2004, 11, 389-396
37. Liu, Z.; Lv, C.; Zhao, W.; Song, Y.; Pei, D.; Xu, T. NR2B-Containing NMDA Receptors Expression and Their Relationship to Apoptosis in Hippocampus of Alzheimer's Disease-Like Rats Neurochem. Res. 2012, 37, 1420-1427
38. Nguyen, C.; Ruda, G. F.; Schipani, A.; Kasinathan, G.; Leal, I.; Musso-Buendia, A.; Kaiser, M.; Brun, R.; Ruiz-Perez, L. M.; Sahlberg, B. L.; Johansson, N. G.; Gonzalez-Pacanowska, D.; Gilbert, I. H. Acyclic nucleoside analogues as inhibitors of Plasmodium falciparum dUTPase J. Med. Chem. 2006, 49, 4183-4195
39. Marvizon, J. C.; Lewin, A. H.; Skolnick, P. 1-Aminocyclopropane carboxylic acid: a potent and selective ligand for the glycine modulatory site of the N-methyl-D-aspartate receptor complex J. Neurochem. 1989, 52, 992-994
40. 3H] ifenprodil binding to the NMDA receptor in rat frontal cortex Br. J. Pharmacol. 2005, 146, 894-902
41. Lowry, O. H.; Rosebrough, N. J.; Farr, A. L.; Randall, R. J. Protein measurement with the Folin phenol reagent J. Biol. Chem. 1951, 193, 265-275
42. Cheng, Y.; Prusoff, W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50% inhibition (I50) of an enzymatic reaction Biochem. Pharmacol. 1973, 22, 3099-3108
43. Abagyan, R.; Totrov, M.; Kuznetsov, D. ICM-A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation J. Comput. Chem. 1994, 15, 488-506
44. Kryger, G.; Harel, M.; Giles, K.; Toker, L.; Velan, B.; Lazar, A.; Kronman, C.; Barak, D.; Ariel, N.; Shafferman, A.; Silman, I.; Sussman, J. L. Structures of recombinant native and E202Q mutant human acetylcholinesterase complexed with the snake-venom toxin fasciculin-II Acta Crystallogr., Sect. D: Biol. Crystallogr. 2000, 56, 1385-1394
45. Altschul, S. F.; Madden, T. L.; Schaffer, A. A.; Zhang, J.; Zhang, Z.; Miller, W.; Lipman, D. J. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs Nucleic Acids Res. 1997, 25, 3389-3402
46. Altschul, S. F.; Wootton, J. C.; Gertz, E. M.; Agarwala, R.; Morgulis, A.; Schaffer, A. A.; Yu, Y. K. Protein database searches using compositionally adjusted substitution matrices FEBS J. 2005, 272, 5101-5109
47. Bottegoni, G.; Kufareva, I.; Totrov, M.; Abagyan, R. Four-dimensional docking: a fast and accurate account of discrete receptor flexibility in ligand docking J. Med. Chem. 2009, 52, 397-406
48. Halgren, T. A. Merck molecular force field. I-V J. Comput. Chem. 1996, 17, 490-641
49. Karakas, E.; Simorowski, N.; Furukawa, H. Subunit arrangement and phenylethanolamine binding in GluN1/GluN2B NMDA receptors Nature 2011, 475, 249-53
50. Bottegoni, G.; Kufareva, I.; Totrov, M.; Abagyan, R. A new method for ligand docking to flexible receptors by dual alanine scanning and refinement (SCARE) J. Comput.-Aided Mol. Des. 2008, 22, 311-325